ADARx Pharmaceuticals Reports Q3 2026 Net Loss of $28.1 Million and Revenue of $2. ...
Clinical-Stage Biotech Posts Higher R&D Spending and a $901 Million Cash Position as Three Phase 2 Trials Advance Related Stocks: ADRX ,
Clinical-Stage Biotech Posts Higher R&D Spending and a $901 Million Cash Position as Three Phase 2 Trials Advance Related Stocks: ADRX ,